Coherus Biosciences Stock Investor Sentiment
| CHRS Stock | USD 0.88 0.02 2.22% |
Slightly above 54% of Coherus BioSciences' investor base is interested to short. The analysis of the overall investor sentiment regarding Coherus BioSciences suggests that many traders are impartial. Coherus BioSciences' investing sentiment can be driven by a variety of factors including economic data, Coherus BioSciences' earnings reports, geopolitical events, and overall market trends.
Coherus BioSciences Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Coherus BioSciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of Coherus BioSciences' Stock prices. Below is the latest headlines and news related to Coherus BioSciences Stock. Current markets are slightly bullish. About 58% of major world exchanges and indexes are currently up. See today's market update for more information.
There is far too much social signal, news, headlines, and media speculation about Coherus BioSciences that are available to investors today. This information is accessible both publicly - through Coherus BioSciences' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Coherus-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Coherus BioSciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Coherus BioSciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Coherus BioSciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Coherus BioSciences alpha.
Coherus Largest EPS Surprises
Earnings surprises can significantly impact Coherus BioSciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-05-06 | 2021-03-31 | 0.07 | 0.01 | -0.06 | 85 | ||
2024-05-09 | 2024-03-31 | -0.24 | -0.32 | -0.08 | 33 | ||
2020-11-05 | 2020-09-30 | 0.41 | 0.33 | -0.08 | 19 | ||
2023-08-02 | 2023-06-30 | -0.48 | -0.38 | 0.1 | 20 | ||
2018-11-08 | 2018-09-30 | -0.77 | -0.87 | -0.1 | 12 | ||
2024-11-06 | 2024-09-30 | -0.12 | -0.01 | 0.11 | 91 |
There is far too much social signal, news, headlines, and media speculation about Coherus BioSciences that are available to investors today. This information is accessible both publicly - through Coherus BioSciences' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Coherus-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Coherus BioSciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Coherus BioSciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Coherus BioSciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Coherus BioSciences alpha.
Coherus BioSciences Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Coherus to Participate in Upcoming Investor Conferences CHRS Stock News | 05/01/2025 |
2 | Acquisition by Dennis Lanfear of 375000 shares of Coherus BioSciences at 0.9462 subject to Rule 16b-3 | 05/07/2025 |
3 | Coherus BioSciences Focuses on Oncology After Divestitures | 05/13/2025 |
4 | Some Coherus BioSciences, Inc. Analysts Just Made A Major Cut To Next Years Estimates | 05/15/2025 |
5 | Disposition of 99988 shares by Wahlstrom Mats of Coherus BioSciences at 0.7389 subject to Rule 16b-3 | 05/23/2025 |
6 | Coherus BioSciences Engages in New Cancer Treatment Collaboration CHRS Stock News | 05/27/2025 |
7 | Coherus Biosciences Rebrands to Coherus Oncology - TipRanks | 05/29/2025 |
8 | Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics | 05/30/2025 |
9 | Acquisition by Satvat Ali J. of 112000 shares of Coherus BioSciences at 0.7904 subject to Rule 16b-3 | 06/12/2025 |
10 | Coherus BioSciences, Inc. Analysts Are Reducing Their Forecasts For This Year - | 07/09/2025 |
11 | Disposition of 3602 shares by Vladimir Vexler of Coherus BioSciences at 10.26 subject to Rule 16b-3 | 07/11/2025 |
12 | What analysts say about Coherus BioSciences Inc. stock - Explosive wealth accumulation - Jammu Links News | 07/18/2025 |
Additional Tools for Coherus Stock Analysis
When running Coherus BioSciences' price analysis, check to measure Coherus BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coherus BioSciences is operating at the current time. Most of Coherus BioSciences' value examination focuses on studying past and present price action to predict the probability of Coherus BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coherus BioSciences' price. Additionally, you may evaluate how the addition of Coherus BioSciences to your portfolios can decrease your overall portfolio volatility.